Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02363868

Enrollment

186

Registered

2015-02-16

Start date

2014-02-28

Completion date

2014-11-30

Last updated

2015-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia (CML)

Brief summary

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Age \>18 years * International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x) * At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013 * Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib)

Exclusion criteria

* History of bone marrow or stem cell transplant as identified in the 6 month pre-period

Design outcomes

Primary

Measure	Time frame	Description
Healthcare costs	Intent-to-treat (ITT) at 6 months	Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy

Secondary

Measure	Time frame	Description
Healthcare costs by line of therapy	Intent-to-treat (ITT) at 6 months	—
Resource utilization by line of therapy	Intent-to-treat (ITT) at 6 months	Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions

Countries

United States

Outcome results